Drug intelligence / Profile preview

GSK3152314A

Development stage: Unknown
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GSK3152314A is a monoclonal antibody developed by GSK for the treatment of immune system diseases, particularly rheumatoid arthritis. It was investigated in Phase 2 clinical trials as an intravenous therapy for patients with active rheumatoid arthritis. The drug acts as an interleukin-17 (IL-17) antagonist, targeting and neutralizing IL-17 to reduce inflammation associated with autoimmune conditions such as rheumatoid arthritis. Development appears to have been discontinued after Phase 2 trials, and it has not reached approval or further development stages.

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on GSK3152314A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3152314A.

Explore the full profile